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ABSTRACT 
Humoral and cell-mediated immune responses of 36 captive foxes to two oral vaccines against 
rabies currently used for foxes in Europe were studied. The Street Alabama Dufferin (SAD) mutant 
Gif (SAG2) vaccine has been selected by double mutation from the SAD virus. The vaccinia 
recombinant virus (V-RG) expresses the rabies glycoprotein. Both vaccines induce similar humoral 
and cell-mediated responses after primary and secondary oral administration. We observed a 
typical anamnestic response, although of a limited duration, after the booster vaccination. 
Therefore, our results suggested that two successive oral vaccination campaigns should not 
significantly improve the immunisation of foxes. Lymphocyte in vitro proliferative response to the 
SAD antigen highlighted the presence in blood of a T-cell specific memory 6 months after 
vaccination. The synthesis of several vulpine cytokines was detected in peripheral blood 
mononuclear cells (PBMC) stimulated by SAD antigen via reverse transcription polymerase chain 
amplification. The data showed a concomitant expression of interleukin (IL)-4 and interferon-y in 
PBMC of vaccinated foxes. No change was detected in the level of IL-2, IL-10 and IL-12 synthesis, 
whereas the pro-inflammatory cytokine tumour necrosis factor-ex seemed involved in the 
activation of naive T lymphocytes. 
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Large-scale annual campaigns of fox oral vaccination, carried out in continental Europe since the 
early 1980s, have led to a drastic reduction of sylvatic rabies incidence [1]. Among the vaccines 
used in the field, those obtained through biotechnology occupy an important position [2]. Two of 
them fulfil all the World Health Organisation (WHO) requirements on innocuity of anti-rabies oral 
vaccines. They experimentally demonstrate an increased safety for numerous target and non-
target wild animal species [3,4]. This concerns the Street Alabama Dufferin (SAD) mutant Gif (SAG2) 
vaccine, a double mutant of the SAD Bern rabies strain obtained by selective growth in the 
presence of specific monoclonal antibodies [5], and the vaccinia-rabies glycoprotein recombinant 
(V-RG) vaccine that expresses the rabies glycoprotein of the ERA SAD derived strain [6–8]. 
However, the elimination of fox rabies may be hampered for two reasons: the persistence of 
residual foci in some areas, and the risk of re-infection of zones already freed, which is parallel to 
an increase in fox population [9]. Therefore, different measures to improve the efficacy of fox oral 
vaccination have been tested in the field (i.e. increase in the number of vaccine baits distributed in 
one campaign [10], vaccination of areas with two passages separated by 15 or 30 days [11], 
vaccination of fox cubs by distributing vaccine baits at the entrance of fox dens [12], vaccination 
during summer period [13]) and need to be optimised in experimental trials on captive foxes. 
Furthermore, protection does not always correlate with a sound level of rabies-neutralising 
antibodies [14–16], suggesting the involvement of protection mechanisms other than antibodies. 
One of the most consistent effects of any vaccine on the immune response is related to T cells; 
therefore, the resistance or the susceptibility to rabies infection might be the result of a differential 
development of rabies-specific T-cell responses. Furthermore, alterations in cytokine profiles 
delivered by T cells to antigen-stimulated B cells may also contribute to differences in the 
production of antibodies following vaccination. Parameters regulating the post-vaccination 
immune response have been studied in mice and humans [17,18], but only very few data are 
available on the relationship between cell-mediated and humoral responses during anti-rabies 
vaccination in fox [19]. To evaluate their contribution in the protection against rabies, we 
investigated the lymphocyte proliferative and neutralising antibodies responses of 36 caged adult 
silver foxes primo- and secundo-vaccinated with the SAG2 or the V-RG vaccine. The production of 
six cytokines known to play a role in the cellular immune response in other mammalian species 
(i.e. interleukin (IL)-2, interferon (IFN)-g, IL-4, IL-10, IL-12 and tumour necrosis factor (TNF)-a) was 
also studied. 
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Materials and methods 
FOXES 
Thirty-six silver foxes (Vulpes vulpes), 1–6 years old, were purchased from the Norwegian Fur 
Breeder’s Association (Oslo, Norway). A 1-month adaptation period was applied from their arrival 
until the beginning of the experiment. The animals were kept in individual cages and observed 
daily. They were fed with a commercial dry food for adult dogs. Water was provided ad libitum. 
VIRUSES 
SAD ANTIGEN PREPARATION 
The SAD parental strain was used as stimulating antigen for in vitro cell stimulation tests. The virus 
was kindly provided by Dr Anne Flamand (Laboratoire de Génétique des Virus, CNRS, Gif-sur-
Yvette, France). The virus was produced on BHK cells and the supernatant was concentrated and 
purified by gradient [20]. The purified SAD virus was then inactivated with b-propiolactone (Sigma, 
St Louis, MO, USA). 
RABIES CHALLENGE VIRUS 
The challenge virus is the supernatant of a 20% homogenate of sub-maxillary salivary glands from 
foxes; it is then kept frozen in liquid nitrogen until use. The virus that has been used in this 
experiment was first isolated from sub-maxillary salivary glands of naturally rabid foxes in 1986 
[21]. That first batch (GS-7) was then passaged three successive times in a single fox [22]. The 
fourth passage (GS-9) is a pool of six pairs of sub-maxillary salivary glands of foxes inoculated with 
the third passaged suspension. The titre of this latter passage was determined by an intracerebral 
inoculation of mice. Immediately after inoculation, the challenge virus was back titrated 
intracerebrally in mice. The titre of the challenge suspension was 103,3 median mouse intracerebral 
lethal doses per millilitre. 
RABIES VACCINES 
V-RG vaccine baits (batch 80U342) supplied by MERIAL SA (Lyon, France) were stored at +4°C until 
use. SAG2 vaccine baits (batch RB2 PO91) supplied by VIRBAC Laboratories (Carros, France) were 
stored at −30°C until use. The titres of the vaccines were verified on receipt, before the beginning of 
the experiment and after each administration to foxes. 
Vaccine titres were expressed in median cell culture infective dose per dose (CCID50/dose). Briefly, 
titra- tions of vaccines were performed in 96-well microtitre plates. Cells (2 × 105) were distributed 
in each well: VERO cells (ATCC No. CCL81) in 100 µl or BSR cells in 200 µl for V-RG and SAG2 
vaccines, respectively. A one in ten serial dilution of the virus was performed; 100 µl for V-RG 
dilutions or 50 µl for SAG2 dilutions were distributed in six replicates. V-RG titration plates were 
incubated for 120 h at 37°C with 5% CO2. The cytopatic effect was observed on an inverted 
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microscope. SAG2 titration plates were incubated for 72 h in the same conditions. As SAG2 virus 
does not induce cell lysis, plates were stained with fluorescein-coupled rabies anti-nucleocapsid 
conjugate. The titre calculation was made by using the neoprobit graphic method [23]. Before the 
experiment, V-RG titrated 108,44 CCID50/dose and SAG2 titrated 108,3 CCID50/dose. After the primary 
vaccination and after the booster vaccination, titres remained unchanged. 
EXPERIMENTAL DESIGN 
Thirty-six foxes were divided into five groups according to age and sex: four experimental groups of 
eight animals (groups A, B, C and D) and a control group of four animals (group T), as detailed in 
Fig. 1. Vaccines were administered by direct instillation into the oral cavity with a syringe on 
manually restrained vigil animals. The instilled volume corresponded to a field dose of V-RG or 
SAG2 vaccine (i.e. 2,7 and 1,8 ml, respectively). On day 0, groups A and B received the SAG2 vaccine, 
and groups C and D received the V-RG vaccine. On day 35, groups B and D were boosted either with 
SAG2 vaccine or V-RG vaccine, respectively. The four control foxes (group T) were not vaccinated. 
On day 195 post-vaccination, all foxes were challenged intramuscularly with 1 ml virus suspension 
(GS-9) into the temporal muscle. The foxes were then daily monitored for clinical signs. In order to 
avoid unnecessary animal suffering, it was planed to euthanise foxes that develop rabies in the 
terminal phase when paralyzed. The observation period had been fixed to 45 days after the death 
of the last control fox. Brain material and sub-maxillary salivary glands of all foxes dying of rabies 
or euthanised at the end of the observation period have been examined for the presence of rabies 
antigen by direct immunofluorescence and cell culture test. 
BLOOD SAMPLING 
Bleeding was carried out by jugular venipuncture on vigil animals. For the neutralising antibody 
test, foxes were bled on days 0 (before primary vaccination), 7, 14, 21, 28, 35, 42, 49, 53, 70, 84, 119, 
161 and 182 (see Fig. 1). For both cell proliferation and cytokine production assays, blood samples 
were collected on day 182 only. 
SEROLOGY 
Rabies-neutralising antibodies were titrated in serum samples by using the fluorescent antibody 
virus neutralisation test [24]. The second WHO Standard for Rabies Immunoglobulin preparation, 
obtained from the Statens Serum Institute (Denmark) and adjusted to a concentration of 0,5 
International Units (IU)/ml, was used as positive reference. Titres were expressed in IU/ml by 
comparison with the titre of the standard serum included in each test. The conventional level of 0,5 
IU/ml has been defined in humans and is considered as indicative of protection against rabies [25]. 
This value is currently used in rabies epidemiological surveys of wildlife. 
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Fig. 1. Schematic representation of the experimental protocol. Animals were assigned to five groups: two groups 
vaccinated once or twice with the SAG2 vaccine (group A and B, respectively), two groups vaccinated once or twice 
with the V-RG vaccine (group C and D, respectively) and one unvaccinated control group (group T). 
CELL PREPARATION 
Blood samples were collected into heparin lithium tubes (Sarstedt, Orsay, France). Peripheral 
blood mononuclear cells (PBMC) were isolated on Ficoll-Hypaque (Pharmacia, Roosendaal, The 
Netherlands) density gradient as previously described [26]. PBMC were then suspended in RPMI 
1640 medium (Gibco BRL, Gent, Belgium) supplemented with 1% non-essential amino acids 
(Gibco), 1 mM sodium pyruvate (Gibco), 100 IU/ml penicillin (Gibco), 100 µg/ml streptomycin 
(Gibco), 5×10-5 M 2-mercaptoethanol (Gibco) and 10% heat-inactivated foetal bovine serum 
(Gibco). 
LYMPHOCYTE PROLIFERATION ASSAY 
PBMC were distributed in 96-well round-bottom plates at 2×105 cells/well (Nunc, Paisley, Scotland). 
The SAD antigen preparation was then added at a final concentration of 2.5 µg/ml, previously 
determined as optimal. Control wells without antigen were set up in parallel. After 6 days of 
incubation at 37°C in a humidified atmosphere with 5% CO2, cultures were pulsed with 
[3H]thymidine (0,8 µCi; specific activity, 2 Ci/mM) (Amersham, Arlington Heights, IL, USA) for the 
last 18 h. [3H]Thymidine incorporation was then measured by liquid scintillation counting. Results 
were expressed as the stimulation index, i.e. the ratio between the counts per minute (cpm) mean 
of sextuplate cultures stimulated with antigen and the cpm mean of sextuplate cultures 
maintained in medium alone. 
CYTOKINE MRNA DETECTION ASSAY 
To measure mRNA expression of IL-2, IFN-g, IL-4, IL-10, IL-12 and TNF-a, PBMC were cultured at 
1×106/ml in six-well plates (Nunc) for 2 days at 37°C with the SAD antigen preparation at the same 
concentration as already described or in medium alone. Cells were then harvested and total RNA 
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was extracted with a commercial kit (High pure RNA isolation kit; Roche). The cDNA was first 
obtained by using reverse transcriptase and 500 ng total RNA extracted from each sample, in a 20 
µl reaction mixture according to conditions recommended by the manufacturer (Roche). The 
reaction mixture was then diluted 1:8 and 5 µl diluted product was used for specific amplification 
of vulpine cytokines. The standard polymerase chain reaction (PCR) was carried out using diluted 
cDNA with 1,25 U Taq polymerase (Roche), 0,2 mM each dNTP (Roche) combined with the PCR 
buffer provided by the manufacturer and 0,2 µM each primer pair (sense and anti- sense) for P-
actin, IFN-g, IL-12, IL-2, IL-4, IL-10 and TNF-a. The primer pairs for PCR were synthesised from 
oligonucleotide consensus sequences already published [27]. Cycling conditions were 95°C, 3 min 
followed by 32–48 cycles of 95°C, 30 s/52 or 60°C, 1 min/72°C, 1 min. PCR products were assayed 
after a restricted number of cycles of amplification to ensure that the analysis of cytokine 
transcripts was performed during the exponential phase of amplification. A negative control 
without cDNA was included in each PCR reaction. PCR products were analysed on ethidium 
bromide-stained agarose gels (1.0%) and expressed as semi-quantitative values using the BIO-
PROFIL gel analyser system (Vilber Lourmat, Marne La Vallée, France). Results were first 
standardised for the relative quantity of total mRNA used in the reverse transcriptase reaction 
through parallel amplification and analysis of transcripts from the housekeeping gene P-actin. The 
results reported for each animal were then expressed as the ratio of cytokine levels found in SAD 
antigen-stimulated cultures to those in the corresponding control cultures without antigen in 
order to consider background production of cytokine mRNAs into account. The specificity of each 
cytokine product was further verified by direct sequencing using the FS polymerase kit (Perkin-
Elmer Cetus). Computer analysis of sequence data showed 90-96% of homology to the published 
canine cytokine sequences using BLAST software. 
STATISTICAL ANALYSIS 
Differences in the neutralising antibody results and in the lymphoproliferative responses between 
groups were analysed using Student’s t-test at a 95% confidence level. Comparison of PCR results 
was performed using the Mann–Whitney U-test with a 95% confidence limit. 
Results 
HUMORAL IMMUNE RESPONSE TO RABIES VACCINATION 
The kinetics of neutralising antibody response within each of the five groups is shown in Fig. 2. 
After primary oral administration, two different patterns of antibody response were observed 
depending on the vaccine used. Neutralising activity was detectable 1 week earlier in foxes of 
groups C and D vaccinated with the V-RG than in those of groups A and B vaccinated with SAG2. 
Furthermore, the levels of antibody titres reached 21 days after primary vaccination were 
significantly higher in foxes that received the V-RG (P<0.05). Results obtained 14 days after the 
booster vaccination showed that neutralising activity was significantly enhanced whatever the 
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Fig. 2. (A) Kinetics of rabies virus neutralising antibody (VNA) mean titres of foxes after primary vaccination with 
the SAG2 (group A) or V-RG (group C). (B) Kinetics of rabies virus neutralising antibody (VNA) mean titres of foxes 
after primary and secondary vaccinations with the SAG2 (group B) or V-RG (group D). Four unvaccinated foxes 
served as controls (group T). The VNA mean titres are expressed in log10 SN50. Arrows, times of vaccination. 
vaccine used. This secondary response was most noticeable in animals that received the V-RG 
vaccine. All control foxes failed to produce any neutralising antibody. The profiles of rabies 
antibodies obtained with these two vaccines differed markedly in a short period of time after 
vaccination. At the end of a period of 6 months, there only remained a significant difference in the 
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levels of neutralising activity between the groups of vaccinated foxes and the group of control 
animals, whatever the vaccination protocol and the vaccine used (P<0.0001). 
RESISTANCE TO RABIES CHALLENGE 
All vaccinated foxes resisted to rabies challenge and all control foxes died from rabies. The mean 
mortality delay (time between virus inoculation and death) was 15 days. The clinical phase lasted 
less than 2 days. Laboratory tests (direct fluorescent antibody test and cell culture infection test) 
confirmed rabies in the control group but were negative on vaccinated animals at the end of the 
observation period. 
Table 1. Rabies virus neutralising antibody (VNA) titres and lymphocyte proliferative responses of PBMC from 
foxes, 182 days after primary vaccination with SAG2 (groups A and B) or V-RG (groups C and D) vaccine 
Fox 
Number 
VNAa Lymphocyte proliferative responseb 
Group A Group B Group C Group D Group T Group A Group B Group C Group D Group T 
1 1,97 1,14 5,92 1,14 <0,3 2,30 2,38 <2,00 2,48 <2,00 
2 1,14 5,92 0,66 10,26 <0,3 2,25 <2,00 5,47 2,03 <2,00 
3 1,14 7,79 10,26 5,92 <0,3 <2,00 2,59 2,77 3,01 <2,00 
4 3,42 7,79 10,26 10,26 <0,3 2,14 8,66 2,11 2,10 <2,00 
5 1,50 4,50 1,97 4,50  <2,00 5,33 6,00 <2,00  
6 4,50 2,60 17,77 3,42  7,53 3,70 6,27 2,11  
7 2,60 0,87 0,66 10,26  3,13 <2,00 2,24 5,83  
8 2,60 5,92 0,50 3,42  2,25 <2,00 2,79 <2,00  
a Rabies virus (CVS strain) neutralising antibody titres are expressed in IU/ml serum. The defined level of 0.5 IU/ml is 
considered indicative of immune protection. 
b Lymphocyte proliferative responses to 2.5 µg/ml inactivated SAD antigen are expressed as stimulation indexes 
(values>2 = significative proliferative response). 
PROLIFERATIVE RESPONSE TO RABIES VIRUS 
Table 1 shows the rabies-specific proliferative responses of fox PBMC 182 days post-vaccination. 
Among the 32 vaccinated foxes, 24 showed significant proliferative responses to the purified SAD 
antigen (groups A–D, P=0.005–0.02), in spite of an individual variability of responses. Several foxes 
(A3, A5, B2, B7, B8, C1, D5 and D8) did not show any proliferative response. Furthermore, the 
responsiveness to virus in the primo-vaccinated foxes with either the SAG2 or the V-RG did not 
significantly differ in magnitude. The booster vaccination did not significantly affect the pro- 
liferative memory responses to rabies virus in any fox of groups A–B and C–D. The reactivity of the 
T-cell level did not correlate with the neutralising antibody titres obtained 182 days post-
vaccination (Table 1): some animals with high neutralising antibody titres (foxes B2, D2 and D4) 
showed relatively low or no virus-specific proliferative T-cell responses and, conversely, in sera of 
animals with high virus-specific proliferative T-cell responses (foxes C2 and C5), low neutralising 
antibody titres were found. 
Published in : Vaccine (2001), vol. 19, n°13-14, pp. 1827–1835 
DOI: 10.1016/s0264-410x(00)00321-2 





Fig. 3. Cytokine mRNAs expression in PBMC from a captive fox after 48 h of stimulation with Con A. PCR 
products b-actin, IFN-g, IL-4, IL-10, IL-12, TNF-a and IL-2 were analyzed on ethidium bromide-stained 1.0% 
agarose gel. For reference, corresponding base pair sizes of a 1 kb DNA marker are shown to the left. 
 
 
Fig. 4. Expression of IFN-g, IL-2, IL-4, IL-10, IL-12 and TNF-a in PBMC of vaccinated foxes to in vitro SAD 
antigen stimulation. After 48 h, cell cultures were treated for the detection of several cytokines mRNA using 
reverse transcriptase-polymerase chain reaction. The left ordinate represents the relative expression of the 
given cytokine in cells (square points) and the right ordinate represents the percentage of individual positive 
cytokine responses (columns). Each square point represents one fox, and the average of the expression level 
is indicated by a red bar. * P<0.05. 
EXPRESSION OF VULPINE CYTOKINES UPON VACCINATION 
The gene sequences of vulpine cytokines were not available in the literature when this study was 
begun. Therefore, we have assayed oligonucleotide consensus primers that have been successfully 
used to amplify canine, porcine, equine and primate mRNA of IFN-g, IL-12, IL-2, IL-4, IL-10 and TNF-
a [27]. In an initial experiment, PBMC of an adult fox were cultured with the Concanavalin A (Con A) 
mitogen at a final concentration of 5 µg/ml for 48 h. Total RNA was then extracted, reverse-
transcribed into cDNA and amplified by PCR using such consensus primer pairs. Reverse 
transcription (RT)-PCR with each cytokine mRNA were repeated in three experiments in order to 
check the consistency of results. As shown in Fig. 3, the RT-PCR products appear as single sharp 
bands and the estimated size of each respective product band corresponds to the predicted 
molecular weight expected from the published cytokine sequences. The absence of band with the 
samples in which the reverse transcriptase enzyme was omitted from the RT reaction demon- 
strated that only mRNA and no genomic DNA was specifically amplified (data not shown). 
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To determine the IL-2, IFN-g, IL-4, IL-10, IL-12 and TNF-a mRNA levels in blood cells following rabies 
vaccinations, PBMC isolated on day 182 from foxes of the five groups were first stimulated in vitro 
with the SAD antigen. Fig. 4 shows the data obtained from the RT-PCR experiments presented as 
the relative ratio of cytokine expression (left ordinate) and as the frequency of responders to SAD 
antigen in fox groups (right ordinate). The criteria for a positive response to stimulant was a value 
of cytokine level greater than the mean ± 3 S.D. of values in the mock-stimulated cultures of each 
group. We found that the relative expression level of IFN-y was two- to threefold higher in cell 
cultures of vaccinated foxes than in those of control animals. Up to 83–100% of foxes in the four 
rabies-immune groups produced IFN-g mRNA in response to in vitro stimulation with SAD antigen. 
However, a significant difference in the amount of IFN-g mRNA was only observed in foxes that had 
been boosted whatever the vaccine used (group B, P=0.04 and group D, P=0.01). In contrast, the 
average expression level of IL-4 mRNA was found to be significantly higher in all groups of animals 
primo- or secundo-vaccinated with either vaccine (P=0.01-0.03). The percentage of IL-4-positive 
responses rose to 43–100% after 2 days of culture. Inversely to the expression of IFN-g and IL-4, 
TNF-a mRNA was specifically induced by SAD antigen in cells of both control and vaccinated 
groups of foxes. The average expression levels were nearly related. Parallel RT-PCR assays using 
the IL-2, IL-10 and IL-12 primers revealed no specific mRNA production in PBMC of the majority of 
studied foxes except a slight difference, but not statistically significant, in the expression level of IL-
2 in cells of vaccinated animals compared with the control ones after in vitro stimulation with the 
SAD antigen. 
Discussion 
The present study was conducted to assess the protective effect conferred to foxes by a booster 
vaccination 35 days after primary vaccination either with SAG2 or V-RG oral vaccines. We have 
studied the kinetics of neutralising activity of experimental foxes and the induction of cellular 
immunity, focusing on in vitro proliferative response and cytokine production of vulpine PBMC. 
The present preliminary results show that, on a qualitative basis, the immune response to the SAG2 
vaccine is indistinguishable from that induced by the V-RG vaccine. 
The antibody response to the first oral vaccination appeared to be induced with both vaccines, 
although the V-RG vaccine elicited a more rapid response than the SAG2 vaccine. After the booster, 
there was evidence of priming with an increase of antibody levels typical of an anamnestic 
response. These results contrast with previous reports stating a long-term inhibition of the efficacy 
of revaccination in vaccinia-primed mice after intravenous injection of vaccinia viruses expressing 
a transgene product such as the glycoprotein of vesicular stomatitis virus or the nucleoprotein of 
lymphocytic choriomeningitis virus [28]. Since, in the present study, we performed vaccination by 
direct instillation into the oral cavity, the route of administration chosen for vaccination may be at 
the origin of this discrepancy. Further analysis of antibody responses 4 months later revealed, 
however, that antibody titres measured in boosted animals were comparable with those detected 
in foxes vaccinated once. A single dose of vaccine seemed to be sufficient not only to initiate the 
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production of memory B cells by the immune system of foxes, but also to maintain long-term 
memory cells and to provide protection against virus challenge. 
The serological results obtained with captive foxes confirm those already observed in the field [11]: 
two successive oral vaccination campaigns using SAG2 baits did not significantly improve the 
immunisation of foxes. In addition to neutralising antibodies, the induction of cell-mediated 
immunity might be an important parameter in rabies-specific protective response of foxes 
following vaccination with SAG2 or V-RG vaccines. As the release of cytokines after rabies 
vaccination has been already studied in mouse [29] and human [30], the identification of such 
cytokines profiles from vulpine T lymphocytes was investigated. Foxes had significantly higher 
lymphoproliferative response to rabies virus post-vaccination whatever the vaccine used, as 
compared with unvaccinated controls. Most of them had sufficient memory cells 6 months later to 
be able to respond in vitro to the SAD parental strain. These results are, however, to be considered 
as preliminary data as the cell-mediated immune response has been studied with samples 
collected on one day only (day 182). Our observations suggest that both vaccines can stimulate 
cell-mediated immune mechanisms. 
To follow-up cell-mediated response, consensus primers described by Rottman et al. [27] were 
used to measure the cytokine mRNA expression in PBMC of foxes after in vitro stimulation by SAD 
parental strain. It should be noted that the choice of the cytokine panel used in the study was 
limited because of the restricted availability of reagents for vulpine cytokines mRNA amplification. 
We demonstrated that PBMC of foxes immunised 6 months before with SAG2 or V-RG vaccine 
significantly express IFN-g and IL-4, but little or no IL-2, IL-10 and IL-12 mRNA, when stimulated in 
vitro with the SAD parental antigen. 
The range of responses observed after the primary vaccination was comparable with that 
evaluated in animals receiving a double oral administration of vaccine. The absence of detection of 
significant IL-2 mRNA levels in PBMC cultures of immunised foxes was surprising in view of 
previous studies that showed rabies-specific production of IL-2 by murine spleno cytes after in 
vitro stimulation with purified inactivated virus [29] or by blood lymphocytes of human vaccinated 
against rabies [30]. This lack of cytokine mRNA production observed in our conditions was not an 
artefact, as IL-2 mRNA was clearly detected in blood cells from vaccinated foxes stimulated with 
Con A. This discrepancy could be due to our experimental conditions, such as the route of 
administration or the type of vaccine (inactivated or not). The lack of IL-2 production by some 
human T-cell lines and clones reactive to rabies virus but that secreted IFN-g under the same 
conditions of antigen stimulation has been already documented [31] as a possible consequence of 
too limited a number of stimulated cells or too small an amount of IL-2, which is rapidly consumed 
by the T cells. Another possible explanation for the absence of IL-2 detection could be the weak 
sensitivity of our technique. 
Although the biological activities of IFN-g, IL-4 and TNF-a are well studied in both mouse and 
human, only few data are known about their activities in foxes and even in similar species such as 
dog, mainly due to the lack of specific tools. Several studies have described large amounts of IFN-g 
induced in vivo by rabies vaccines early after the primary vaccination, pointing out the important 
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antiviral role played by this cytokine as a first-line defence mechanism of the organism (for a 
review, see King and Turner [32]). This cytokine was also produced in vitro by antigen-specific T 
cells from human recipients of rabies vaccine or by splenocytes of primed mice cultured in the 
presence of rabies antigenpresenting cells [31,33]. Therefore, a strong IFN-g expression in PBMC of 
boosted foxes with SAG2 or V-RG vaccines may be not only an indicator of a T-cell response, but 
also a mean to evaluate the capability of the vaccinated foxes to control rabies infection. The 
significance of the concomitant expression of both IL-4 and IFN-g after in vitro stimulation with 
rabies anti- gens in PBMC of vaccinated foxes remain to be determined. 
In summary, we have shown in this paper that humoral immune responses to oral vaccination with 
SAG2 or V-RG vaccines is not significantly increased when repeating vaccination 35 days later. Our 
preliminary data on cell immunity yields the same conclusion. These results could suggest that 
only one distribution of baits is necessary in field conditions during each oral rabies fox vaccination 
campaign. 
To our knowledge, although preliminary, this is the first study that simultaneously evaluate rabies 
vaccine-induced antibody response, PBMC proliferation and cytokine expression in foxes. Further 
studies will be needed to confirm our results by collecting more biological samples and 
determining the relative importance of the T-dependent cytokines identified in regulating the fox 
immune response to rabies virus. 
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